The anti-cancer drug developed by Sathees C. Raghavan of the Department of Biochemistry, Indian Institute of Science (IISc.), Bengaluru, and his team is expected to go for clinical trials before it is commercially launched.

Research on SCR-7, the drug molecule named after the professor, has been published and is considered to be path breaking.

“SCR-7 can block the repair of broken DNA in a cancer cell, thus preventing the propagation of cancer cells,” Dr. Raghavan told reporters after sharing experiences of his research with scientists and delegates at the 103rd Indian Science Congress here on Wednesday.